Product · #16 of 27 · multi-symptom
Happy V Menopause Relief AM + PM
Capsule (am + pm) from Happy V, made by Happy V. Daily serving: 1 AM capsule + 1 PM capsule.
Last updated · Price and ratings checked Nov 19, 2026
In short: Happy V Menopause Relief AM + PM scores 48.9/100 in our ranking (#16 of 27). It costs $2.00 a day at the regular price. Evidence: pollen extract + genistein 40 mg; no product trial; best ingredient grade B- (Soy isoflavones & genistein). No NSF registry listing was confirmed.
Pros
- None stood out.
Cons
- No NSF registry listing confirmed.
- Expensive: $2.00 a day at the label dose.
Flags
Drug interactionsEstrogen metabolism
Score breakdown
Full label: what's in it
| Ingredient (as labeled) | Per day | Evidence page |
|---|---|---|
| Graminex G63 flower pollen extract (AM 160 + PM 160) | 320 mg | Flower pollen extract C |
| DIM (AM) | 100 mg | DIM D |
| Lifenol hop extract (AM) | 85 mg | Hops (8-PN) C- |
| Sensoril ashwagandha (AM 75 + PM 75) | 150 mg | Ashwagandha C |
| Genistein from Sophora japonica (AM) | 40 mg | Soy isoflavones & genistein B- |
| BroccoRaphanin Plus broccoli seed extract (AM) | 25 mg | Not in our evidence library |
| HMRlignan Norway spruce lignans (AM 18 + PM 18) | 36 mg | Not in our evidence library |
| Red clover extract (PM) | 75 mg | Red clover C+ |
| 5-HTP (PM) | 75 mg | Not in our evidence library |
| Vitamin B6 (AM 1.7 pyridoxine + PM 20 P5P) | 21.7 mg | Not in our evidence library |
| Vitamin B12 (AM) | 2.4 mcg | Not in our evidence library |
| Magnesium (PM) | 25 mg | Magnesium D |
| Zinc (PM) | 18 mg | Not in our evidence library |
Full Supplement Facts are on the official page.
Evidence
Our evidence score: 22/40, because: pollen extract + genistein 40 mg; no product trial.
Product-level research: we found no published trial of this exact product, so its evidence comes from studies of its ingredients.
Ingredient evidence
- Flower pollen extract C (320 mg here)
Purified flower-pollen extract (the active in Relizen) is a non-hormonal ingredient studied for occasional hot flashes and night sweats*. Only two small placebo-controlled trials exist, and pooled controlled data were not statistically significant. The Menopause Society 2023: Not recommended (Level III). - DIM D (100 mg here)
DIM (3,3'-diindolylmethane) changes how the body breaks down estrogen. Its effect on menopause symptoms has not been tested in a single clinical trial. The Menopause Society 2023: Not assessed. - Hops (8-PN) C- (85 mg here)
Hop extract, a source of the potent plant estrogen 8-prenylnaringenin (8-PN), has been studied in a few small trials for occasional hot flashes*, with mixed results. The Menopause Society 2023: Not assessed. - Ashwagandha C (150 mg here)
Ashwagandha root extract has been studied for occasional stress, sleep quality and common symptoms in perimenopause and menopause* in a few small placebo-controlled trials, all run in India. The Menopause Society 2023: Not assessed. - Soy isoflavones & genistein B- (40 mg here)
Soy isoflavones (including genistein) are the most widely studied supplement group for occasional hot flashes associated with menopause*. Meta-analyses find modest average effects, such as about 20% fewer hot flashes than placebo in one analysis, and results vary between trials. The Menopause Society 2023: Not recommended (Level II) – mixed evidence. - Red clover C+ (75 mg here)
Red clover isoflavones have been studied for occasional hot flashes*. Some meta-analyses report short-term effects, but a 12-month NIH-funded trial and a Cochrane review found no clear benefit over placebo. The Menopause Society 2023: Not specifically named (supplements not recommended). - Magnesium D (25 mg here)
Magnesium supports normal muscle and nerve function*. In the one large menopause trial (289 women), it did not reduce hot flashes compared with placebo. The Menopause Society 2023: Not assessed.
Studies
Studies on its ingredients (20)
-
Femal, a herbal remedy made from pollen extracts, reduces hot flushes and improves quality of life in menopausal women: a randomized, placebo-controlled, parallel study.
64 women took Femal flower-pollen extract or placebo for 3 months; 54 finished. Hot flashes fell more on the pollen extract, but this is a single small study.
- Who
- 64 randomized (54 completed)
- Dose
- Femal (pollen extract) 2 tablets/day
- Duration
- 3 months
- Result
- 65% responders vs 38% placebo (P<.006); diary hot flushes 27% lower vs placebo.
- Funding
- Not stated in abstract (Femal is a Natumin Pharma product). Funding not stated
-
The efficacy of purified pollen extract for reducing vasomotor symptoms in women: a systematic review and meta-analysis.
Researchers pooled every study of the pollen extract in Relizen. Women improved over 3 months, but when compared with placebo the difference disappeared, suggesting much of the benefit may be placebo. No significant side effects were seen.
- Who
- 5 studies (1 RCT + 4 observational), 420 women
- Dose
- purified cytoplasm of pollen (PureCyTonin/Relizen)
- Duration
- 3 months
- Result
- Large improvements before-vs-after, but when only controlled studies were pooled the effect was not statistically significant – may be placebo effect.
- Funding
- Authors reported no conflicts. Independent / academic
-
A prospective, multicenter, randomized, double-blind placebo-controlled trial on purified and specific Cytoplasmic pollen extract for hot flashes in breast cancer survivors.
39 breast-cancer survivors took the Relizen pollen ingredient or placebo for 3 months. Hot flashes fell in the active group, but the trial was very small and mainly compared women to their own starting point.
- Who
- 39 breast-cancer survivors
- Dose
- PureCyTonin (Relizen/Sérélys ingredient)
- Duration
- 3 months
- Result
- Fewer diary hot flashes vs baseline (P=.02) in the active group; well tolerated.
- Funding
- Not stated in abstract. Funding not stated
-
The impact of 3,3'-diindolylmethane on estradiol and estrogen metabolism in postmenopausal women using a transdermal estradiol patch.
In women already using an estrogen patch, those also taking DIM had clearly different estrogen breakdown products in urine, raising the possibility that DIM could interfere with hormone therapy. There are no trials showing DIM relieves menopause symptoms.
- Who
- postmenopausal women on transdermal estradiol (observational)
- Dose
- DIM supplement
- Duration
- cross-sectional
- Result
- DIM significantly altered 6 of 10 urinary estrogen metabolites; may blunt hormone therapy.
- Funding
- Not stated in abstract. Funding not stated
-
A first prospective, randomized, double-blind, placebo-controlled study on the use of a standardized hop extract to alleviate menopausal discomforts.
67 Belgian women took a hop extract or placebo for 12 weeks. There was an early benefit at 6 weeks that was no longer significant at 12 weeks.
- Who
- 67 women
- Dose
- hop extract 100 or 250 µg 8-PN/day
- Duration
- 12 weeks
- Result
- 100 µg beat placebo at 6 weeks but not 12 weeks; no dose-response.
- Funding
- Not stated in abstract. Funding not stated
-
A randomized, double-blind, placebo-controlled, cross-over pilot study on the use of a standardized hop extract to alleviate menopausal discomforts.
36 Finnish women took a hop extract and placebo for 8 weeks each. Overall it did not beat placebo.
- Who
- 36 women (crossover)
- Dose
- standardized hop extract
- Duration
- 16 weeks (8+8)
- Result
- No significant overall effect; some time-specific improvements.
- Funding
- Not stated in abstract. Funding not stated
-
The effect of Hop (Humulus lupulus L.) on early menopausal symptoms and hot flashes: A randomized placebo-controlled trial.
120 Iranian women took hops or placebo for 12 weeks and reported fewer hot flashes with hops. One unreplicated study.
- Who
- 120 women (Iran)
- Dose
- hop tablets
- Duration
- 12 weeks
- Result
- Greene score and hot-flash counts lower vs placebo at weeks 4, 8, 12.
- Funding
- Academic (Tabriz Univ.). Independent / academic
-
Effect of an ashwagandha (Withania Somnifera) root extract on climacteric symptoms in women during perimenopause: A randomized, double-blind, placebo-controlled study.
100 Indian women in perimenopause took ashwagandha root extract (300 mg twice a day) or placebo for 8 weeks. Menopause symptoms and quality of life improved more with ashwagandha, and hormone levels shifted. The study was short and not yet repeated outside India.
- Who
- 100 perimenopausal women (91 completed)
- Dose
- ashwagandha root extract 300 mg twice daily
- Duration
- 8 weeks
- Result
- Total MRS and MENQoL improved vs placebo; estradiol up, FSH/LH down.
- Funding
- Not stated in abstract; Indian investigators (ingredient-supplier funding typical but not verified). Funding not stated
-
A prospective, randomized, double-blind, placebo-controlled study on efficacy and safety of Ashwagandha root extract (Withania somnifera) for managing menopausal symptoms in women.
60 Indian women took ashwagandha root extract or placebo for 8 weeks; symptoms, hot flashes and stress improved more with ashwagandha. Small and short.
- Who
- 60 women aged 45–55
- Dose
- ashwagandha root extract
- Duration
- 56 days
- Result
- MRS, hot-flash events and stress scores improved vs placebo.
- Funding
- Authors declared no conflicts. Independent / academic
-
Effects of Withania somnifera root extract on sleep quality, body composition, and menopausal symptoms in postmenopausal women: a randomized, double-blind, placebo-controlled trial.
66 Indian postmenopausal women took ashwagandha 600 mg a day or placebo for 12 weeks; sleep and menopause symptoms improved more with ashwagandha.
- Who
- 66 postmenopausal women (63 completed)
- Dose
- ashwagandha root extract 600 mg/day
- Duration
- 12 weeks
- Result
- Better sleep quality (PSQI -5.2 vs -0.8), menopause symptoms and body fat vs placebo; no BMD change.
- Funding
- No conflicts reported. Independent / academic
-
Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial.
The US government-funded HALT study followed 351 women for a year. Black cohosh (160 mg a day), a 10-herb blend, and the blend plus more soy food did no better than a dummy pill for hot flashes, while hormone therapy clearly worked.
- Who
- 351 women aged 45–55
- Dose
- black cohosh 160 mg/day; multibotanical; multibotanical + soy diet; hormone therapy; placebo
- Duration
- 12 months
- Result
- No herbal arm differed from placebo at 3, 6 or 12 months (<1 hot flash/day difference); hormone therapy reduced ~4 symptoms/day vs placebo.
- Funding
- US NIH (NCCAM/NIA) – HALT study, independent. Independent / academic
-
Phytoestrogens for menopausal vasomotor symptoms.
An independent Cochrane review of 43 trials found no conclusive proof that phytoestrogens (soy, red clover) reduce hot flashes. High-genistein soy extracts looked more promising, and placebo effects were large.
- Who
- 43 RCTs, 4,364 women
- Dose
- various phytoestrogens
- Duration
- various
- Result
- No conclusive evidence of reduced hot flushes; Promensil (red clover) not better than placebo (MD -0.93/day, NS); genistein >30 mg/day may help; strong placebo effect.
- Funding
- Cochrane review (independent). Independent / academic
-
Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials.
Pooling 17 trials, soy isoflavone supplements (about 54 mg a day) cut hot-flash frequency by about a fifth more than placebo. Products higher in genistein worked better. Results varied widely between studies.
- Who
- 17 RCTs in meta-analysis
- Dose
- median 54 mg isoflavones/day
- Duration
- 6 weeks–12 months
- Result
- Hot-flash frequency -20.6% and severity -26.2% vs placebo; >18.8 mg genistein about twice as effective.
- Funding
- Academic (Japan/US); funding not stated in abstract. Funding not stated
-
Use of Plant-Based Therapies and Menopausal Symptoms: A Systematic Review and Meta-analysis.
A JAMA analysis of 62 studies found plant estrogens such as soy cut about one hot flash a day compared with placebo – a modest effect – and most studies were of low quality.
- Who
- 62 studies, 6,653 women
- Dose
- phytoestrogens and other plant therapies
- Duration
- various
- Result
- Phytoestrogens: -1.31 hot flashes/day; soy isoflavones -0.79/day; 74% of RCTs at high risk of bias.
- Funding
- Academic (Erasmus MC); industry co-funding reported in paper is not verified here. Industry-linked
-
Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study.
Italian women took high-dose soy isoflavones (150 mg a day) or placebo for 5 years. A small number on soy developed thickening of the womb lining (3.4% vs 0%), so long-term high doses deserve caution.
- Who
- 376 women with intact uterus
- Dose
- soy isoflavones 150 mg/day
- Duration
- 5 years
- Result
- Endometrial hyperplasia in 3.37% on soy vs 0% placebo; no cancers.
- Funding
- Not stated in abstract. Funding not stated
-
Soy and isoflavones consumption and breast cancer survival and recurrence: a systematic review and meta-analysis.
Studies following women with breast cancer found eating soy was linked to lower recurrence, not higher. These looked at soy food, not concentrated supplements.
- Who
- 12 cohort studies, 37,275 breast-cancer patients
- Dose
- dietary soy/isoflavone intake
- Duration
- observational
- Result
- Pre- and post-diagnosis soy intake associated with lower recurrence; no harm signal.
- Funding
- Academic. Independent / academic
-
Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial.
In a year-long, government-funded trial, women took black cohosh, red clover, hormone therapy or a dummy pill. Only hormones beat placebo for hot flashes; both herbs looked safe but did not reduce hot flashes more than placebo.
- Who
- 89 women (4 arms)
- Dose
- standardized black cohosh and red clover extracts vs CEE/MPA vs placebo
- Duration
- 12 months
- Result
- Hot-flash reduction: black cohosh 34%, red clover 57%, placebo 63%, hormones 94%; neither botanical beat placebo. Both appeared safe over 12 months.
- Funding
- NIH (NCCAM/ODS) botanical center, University of Illinois – independent. Independent / academic
-
Evaluation of Clinical Meaningfulness of Red Clover (Trifolium pratense L.) Extract to Relieve Hot Flushes and Menopausal Symptoms in Peri- and Post-Menopausal Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Pooling 8 trials, red clover reduced hot flashes by about 1–2 a day more than placebo, mostly in women with frequent hot flashes taking higher doses.
- Who
- 8 trials (10 comparisons)
- Dose
- red clover isoflavones
- Duration
- ~12 weeks
- Result
- -1.73 hot flushes/day vs placebo (95% CI -3.28 to -0.18), mainly in women with ≥5/day and ≥80 mg isoflavones.
- Funding
- Authors declared no conflicts. Independent / academic
-
Red clover extract for alleviating hot flushes in postmenopausal women: a meta-analysis.
A review found red clover modestly reduced hot flashes over 3–4 months, but the benefit was no longer seen at 12 months.
- Who
- meta-analysis
- Dose
- red clover extract
- Duration
- 3–4 months and 12 months
- Result
- Effective at 3–4 months (MD -1.34/day) but not at 12 months.
- Funding
- Academic (Monash). Independent / academic
-
North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes.
289 women who had breast cancer took magnesium (800 or 1,200 mg a day) or placebo. Magnesium did not reduce hot flashes and caused more diarrhea.
- Who
- 289 women with breast-cancer history
- Dose
- magnesium oxide 800 or 1,200 mg/day
- Duration
- 8 weeks (per protocol)
- Result
- No difference vs placebo in hot-flash score or frequency; more diarrhea.
- Funding
- NCI/Alliance cooperative group (public). Independent / academic
The Menopause Society's 2023 statement is in the study library.
Price
| Regular one-time price | $59.99 (60 units, 30 days at label dose) |
|---|---|
| Cost per day | $2.00 |
| Subscription | $53.99/mo (1-mo), $50.99/mo (3-mo), $47.99/mo (6-mo); BF extra 20% first sub |
| Price notes | Amazon B0HLN3CTJL currently unavailable |
| In stock when checked | Yes |
| Checked | Nov 19, 2026 |
Ratings
Amazon: No Amazon rating
Star ratings reflect buyer satisfaction, not clinical effect.
Certifications and claims
Verified in a public registry
- No registry listing found.
Claims made by the brand
- “tested for purity/contaminants per FDA cGMP” Brand claim
- “clinically studied ingredients at effective doses” Brand claim
Registry check: NSF/ANSI 173 ('Happy V'): not found
Who's behind it
| Brand | Happy V |
|---|---|
| Owner / company | Happy V (Miramar, FL). |
| Founders | Daniella Levy (CEO) & Hans Graubard (COO). |
| Where it's made | Own US manufacturing facility (brand claim). Brand claim |
| Medical advisors named |
|
| Source | happyv.com |
Flags & safety
Legal, regulatory and quality flags
- 5-HTP: serotonergic – caution with SSRIs/SNRIs.
- Contains DIM, which changes how the body breaks down estrogen and may alter the effect of transdermal estradiol (Newman 2025). study
- ConsumerLab 'Menopause Supplements Review' (soy/red clover isoflavones, black cohosh, progesterone cream) last updated 2026-10-29; product results are members-only (not accessed). Public summary: ≥50 mg soy isoflavones or ≥15 mg genistein / 28 mg daidzein for effect; only 1/3–1/2 of women are equol producers. Past rounds found products with 30–59% of listed isoflavones and a black cohosh product with lead. consumerlab.com
Ingredient safety notes
- Flower pollen extract: Non-estrogenic in preclinical work; no significant adverse effects reported. Pollen allergy theoretical.
- DIM: Alters estrogen metabolism; may change effect of transdermal estradiol (Newman 2025).
- Hops (8-PN): 8-PN is a potent phytoestrogen – caution in hormone-sensitive conditions.
- Ashwagandha: Rare liver-injury case reports exist in the literature (not reviewed here); avoid in pregnancy and with thyroid medication — standard cautions (not verified here). Trials reported raised estradiol, lower FSH/LH. Unverified
- Soy isoflavones & genistein: Soy is a common allergen. In a 5-year trial of 150 mg/day isoflavones, endometrial hyperplasia occurred in 3.4% vs 0% on placebo (Unfer 2004). Cohort studies of soy foods in breast-cancer survivors link them with lower recurrence and show no harm signal, but the safety of concentrated isoflavone supplements after breast cancer is uncertain (NCCIH).
- Red clover: Phytoestrogen – same caution as isoflavones in hormone-sensitive conditions; 12-month safety acceptable in Geller 2009.
- Magnesium: Diarrhea at 800–1,200 mg magnesium oxide.
Sources
Talk to a clinician first
The Menopause Society's 2023 nonhormone position statement does not recommend any dietary supplement or herbal remedy for hot flashes, because the research is limited or mixed. Hormone therapy is an option for many women, and the statement lists non-hormonal options with evidence behind them: CBT, clinical hypnosis, SSRIs/SNRIs, gabapentin, fezolinetant (Level I), oxybutynin (I–II), weight loss, stellate ganglion block (II–III).
If hot flashes, night sweats, sleep or mood are affecting your life, talk to a clinician first. If you still want to try a supplement, the rankings below show what is actually in each one, what the research found, and who is behind it. Sources: position statement (PDF) · PubMed.
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Solynes does not sell supplements; descriptions summarize published research and are not medical advice.